News
Avalyn seeks $300m from its IPO

Avalyn seeks $300m from its IPO

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

Featured Content

Newsletters and Deep Dive
digital magazine

Latest News

News
Avalyn seeks $300m from its IPO

Avalyn seeks $300m from its IPO

Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.

Views & Analysis

White Papers & Webinar

Podcasts & Video

Partner Content